Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bone marrow-derived mesenchymal stem cells (First Affiliated Hospital, Sun Yat-Sen University)
- Development stage
- Unknown
- Lead developer
- The First Affiliated Hospital of Sun Yat-sen University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Bone marrow-derived mesenchymal stem cells (BM-MSCs) are an investigational allogeneic cell therapy being developed and evaluated by the First Affiliated Hospital, Sun Yat-Sen University. These cells are harvested from third-party healthy volunteer donors and are utilized for their potent immunomodulatory and regenerative properties. In the context of kidney transplantation, particularly from donors after citizen death (DCD), BM-MSCs are administered intravenously to mitigate the risk of graft rejection and delayed graft function (DGF). The therapeutic effect is mediated through the suppression of inflammatory T-cell and B-cell responses, modulation of dendritic cell maturation, and the induction of regulatory T-cells (Tregs), which collectively promote an environment of immune tolerance and facilitate tissue repair in the transplanted organ.
- Other names
- allogeneic bone marrow-derived mesenchymal stem cellsmesenchymal stem cellsBM-MSC
Beyond the preview
Go deeper on bone marrow-derived mesenchymal stem cells (First Affiliated Hospital, Sun Yat-Sen University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bone marrow-derived mesenchymal stem cells (First Affiliated Hospital, Sun Yat-Sen University).